Non-Profit Organizations Invited to Apply for Grants to Improve Access to Diabetes Care
KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) announced today the launch of a new initiative, Bridging the Gap: Reducing Disparities in Diabetes Care (Bridging the Gap), to improve access to high-quality diabetes care and reduce health disparities for vulnerable and underserved populations in the United States. With $10 million in funding from the Foundation over five years, Bridging the Gap will build sustainable partnerships across sectors to support innovative approaches to diabetes treatment and management.
Bridging the Gap partners will work to ensure that individuals with diabetes can benefit not only from improved medical care, but also from interventions that address the multiple social and environmental factors outside of the health care system that influence health and well-being.
“Diabetes is a significant population health concern, with more than 29 million Americans living with the disease. There is a higher prevalence of diabetes in underserved communities, where many patients do not receive the help they need to effectively manage their health,” said Dr. Julie L. Gerberding, chief patient officer, Merck and chief executive officer, Merck Foundation. “Through Bridging the Gap, we will work with our partners to promote sustainable improvements in diabetes care for those who need it the most.”
Non-profit organizations in the United States are invited to apply for a grant to support the implementation of multifaceted programs focused on type 2 diabetes that will:
As part of Bridging the Gap, the Foundation will support a comprehensive evaluation to assess the impact of the initiative and identify novel intersectoral approaches to reduce diabetes disparities.
Interested organizations can learn more about the application process, eligibility requirements, guidance for proposed interventions and deadlines from the Foundation’s Call for Proposals on our website.
An external advisory committee will review the invited proposals based on specific criteria outlined in the Call for Proposals. Grant awards will be announced in mid-2017.
About The Merck Foundation
The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company and is Merck’s chief source of funding support to qualified non-profit charitable organizations. Since its inception, the Merck Foundation has contributed more than $844 million to support important initiatives that address societal needs and are consistent with Merck’s overall mission to help the world be well. For more information, visit www.merckgiving.com.
Merck
Lainie Keller, 908-236-5036
or
Jeanine Clemente, 908-236-5059
Copyright © 2009- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
Merck, known as MSD outside the United States and Canada, is a leading research-driven healthcare company.